Correlation of serum neuropeptide Y level with the number of diseased coronary vessels in coronary heart disease patients

doi:10.3969/j.issn.1673-8640.2017.011.022

Abstract

Abstract:

Objective To investigate the correlation of serum neuropeptide Y（NPY） level with the number of diseased coronary vessels in coronary heart disease（CHD）. Methods A total of 172 patients with coronary artery stenosis ≥50% by selective coronary angiography were enrolled as CHD group. They were classified into 3 groups according to the number of diseased coronary vessels（one-vessel disease,double-vessel disease and triple-vessel disease）. A total of 180 patients without coronary artery stenosis or with coronary artery stenosis <50% by selective coronary angiography were enrolled as control group. Serum NPY levels were determined by enzyme-linked immunosorbent assay. The clinical data about blood pressure,blood glucose,blood lipid and so on were collected. Results There was statistical significance between CHD group and control group in sex,age,smoking,hypertension and diabetes mellitus（P<0.05）. There was no statistical significance for body mass index （BMI） and hyperlipidemia between the 2 groups（P>0.05）. The level of NPY in CHD group was higher than that in control group（P<0.05）. The NPY levels in one-vessel disease,double-vessel disease and triple-vessel disease groups had statistical significance（P<0.05）. With the number of diseased coronary vessels increasing,the proportion of males increased gradually,and the proportion of triple-vessel disease in males was higher than that in females（P<0.05）. The age of onset in females was older than that in males（P<0.05）. Conclusions Serum NPY level may reflect the degree of CHD and the number of diseased coronary vessels.

Key words: Neuropeptide Y, Coronary heart disease, Diseased coronary vessel

CLC Number:

R446.1

MIAO Yingxin, GAN Jiemin, CHEN Jie, SHI Hong, JIANG Wenrong, ZHAO Hu. Correlation of serum neuropeptide Y level with the number of diseased coronary vessels in coronary heart disease patients[J]. Laboratory Medicine, 2017, 32(11): 1039-1042.

Figures/Tables 2

References 13

[1]	FALLGREN B,ARLOCK P,EDVINSSON L.Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction by an intracellular calcium-dependent mechanism[J]. J Auton Nerv Syst,1993,44(2-3):151-159.
[2]	LI L,JÖNSSON-RYLANDER A C,ABE K ,et al. Chronic stress induces rapid occlusion of angioplasty-injured rat carotid artery by activating neuropeptide Y and its Y1 receptors[J]. Arterioscler Thromb Vasc Biol,2005,25(10):2075-2080.
[3]	ESLER M,KAYE D.Sympathetic nervous system activation in essential hypertension,cardiac failure and psychosomatic heart disease[J]. J Cardiovasc Pharmacol,2000,35(7 Suppl 4):S1-S7.
[4]	ZHU P,SUN W,ZHANG C,et al.The role of neuropeptide Y in pathophysiology of atherosclerotic cardiovascular disease[J]. Int J Cardiol,2016,220:235-241.
[5]	TILAN J U,EVERHART L M,ABE K,et al.Platelet neuropeptide Y is critical for ischemic revascularization in mice[J]. FASEB J,2013,27(6):2244-2255.
[6]	GAO B,LI L,ZHU P,et al.Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE-/- knockout mice fed normal diet[J]. Atherosclerosis,2015,243(1):268-277.
[7]	LI L,LEE E W,JI H,et al.Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery[J]. Arterioscler Thromb Vasc Biol,2003,23(7):1204-1210.
[8]	RUOHONEN S T,ABE K,KERO M,et al.Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury[J]. Peptides,2009,30(4):715-720.
[9]	LAGRAAUW H M,WESTRA M M,BOT M,et al.Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation[J]. Atherosclerosis,2014,235(1):196-203.
[10]	成蓓,张银环,吴剑萍,等. 冠心病患者血浆神经肽Y水平的临床观察[J]. 临床心血管病杂志,1995,11(2):73-75.
[11]	刘润梅,张志寿,陈素娟,等. 冠心病患者血浆神经肽Y水平变化及其临床意义[J]. 心脏杂志,2000,12(1):13-15.
[12]	田海玲,王国宏. 冠心病患者血浆降钙素基因相关肽和神经肽Y测定的临床意义[J]. 检验医学,2000,15(4):237.
[13]	LI L,NAJAFI A H,KITLINSKA J B,et al.Of mice and men:neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability[J]. J Cardiovasc Transl Res,2011,4(3):351-362.

组别	例数	性别[例（%）]		年龄（岁）	吸烟[例（%）]		高血压[例（%）]
组别	例数	男	女	年龄（岁）	是	否	是	否
CHD组	172	118（68.60）	54（31.40）	69.76±9.24	73 （42.44）	99 （57.56）	132 （76.74）	40 （25.26）
对照组	180	96（53.33）	84（46.67）	63.10±10.01	56 （31.11）	123 （68.89）	117 （65.00）	63 （35.00）
统计值		8.61		6.30	4.86		5.86
P值		0.003		<0.05	0.03		0.02
组别	糖尿病[例（%）]		高脂血症[例（%）]		BMI[例（%）]
组别	是	否	是	否	<18.5 kg/m²	18.5~23.9 kg/m²	24.0~27.9 kg/m²	28.0 kg/m²
CHD组	52（30.23）	120（69.77）	49（28.49）	123（71.51）	5 （2.91）	72 （41.86）	67 （38.95）	28 （16.28）
对照组	19（10.56）	161（89.44）	50（27.78）	130（72.22）	2 （1.11）	88 （48.89）	70 （38.89）	20 （11.11）
统计值	21.15		0.02		4.11
P值	0.000 004		0.88		0.25

组别	例数	性别[例（%）]		年龄（岁）	吸烟[例（%）]		高血压[例（%）]
组别	例数	男	女	年龄（岁）	是	否	是	否
CHD组	172	118（68.60）	54（31.40）	69.76±9.24	73 （42.44）	99 （57.56）	132 （76.74）	40 （25.26）
对照组	180	96（53.33）	84（46.67）	63.10±10.01	56 （31.11）	123 （68.89）	117 （65.00）	63 （35.00）
统计值		8.61		6.30	4.86		5.86
P值		0.003		<0.05	0.03		0.02
组别	糖尿病[例（%）]		高脂血症[例（%）]		BMI[例（%）]
组别	是	否	是	否	<18.5 kg/m²	18.5~23.9 kg/m²	24.0~27.9 kg/m²	28.0 kg/m²
CHD组	52（30.23）	120（69.77）	49（28.49）	123（71.51）	5 （2.91）	72 （41.86）	67 （38.95）	28 （16.28）
对照组	19（10.56）	161（89.44）	50（27.78）	130（72.22）	2 （1.11）	88 （48.89）	70 （38.89）	20 （11.11）
统计值	21.15		0.02		4.11
P值	0.000 004		0.88		0.25

组别	例数	年龄（岁）	NPY（ng/L）
对照组	180		247.04±31.05
男	96	62.10±10.29	259.31±26.23
女	84	64.27±9.25	245.16±23.18
CHD组	172		363.70±53.72^*
单支病变组	67		323.08±32.99^*﹟
男	46	65.78±1.47^Δ	338.50±22.78
女	21	71.48±8.35	289.29±26.06
双支病变组	31		368.95±47.76^*﹟
男	20	67.25±11.66^Δ	397.70±27.91
女	11	74.18±7.31	316.67±26.54
3支病变组	74		398.28±45.84^*
男	52	68.62±10.06^Δ	420.12±32.61
女	22	75.27±7.61	346.67±27.39

组别	例数	年龄（岁）	NPY（ng/L）
对照组	180		247.04±31.05
男	96	62.10±10.29	259.31±26.23
女	84	64.27±9.25	245.16±23.18
CHD组	172		363.70±53.72^*
单支病变组	67		323.08±32.99^*﹟
男	46	65.78±1.47^Δ	338.50±22.78
女	21	71.48±8.35	289.29±26.06
双支病变组	31		368.95±47.76^*﹟
男	20	67.25±11.66^Δ	397.70±27.91
女	11	74.18±7.31	316.67±26.54
3支病变组	74		398.28±45.84^*
男	52	68.62±10.06^Δ	420.12±32.61
女	22	75.27±7.61	346.67±27.39

[1]	MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664.
[2]	WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589.
[3]	LIU Jinyan, ZHAO Juntao, XIANG Mingjie. Mechanism and application of serum amyloid A in clinical diseases [J]. Laboratory Medicine, 2021, 36(7): 756-760.
[4]	WANG Linlin, FAN Jun, YE Chenyu, YING Chunmei. Correlation between blood lipid and carotid atherosclerotic plaque in elderly patients with coronary heart disease [J]. Laboratory Medicine, 2021, 36(6): 618-622.
[5]	ZHANG Xilin, SHEN Yifeng, ZHU Jing, ZHANG Chunyan, SHAO Wenqi, WANG Beili, GUO Wei. Roles of AST,m-AST and m-AST/AST in preoperative and postoperative evaluation of patients with CHD and AMI [J]. Laboratory Medicine, 2021, 36(5): 471-476.
[6]	WANG Beili, LI Huijun, WU Yan’an, DAI Wanru, LI Yihao, GUO Wei, PAN Baishen. Correlation between serum biochemical parameters and the degree of coronary artery stenosis in patients with coronary heart disease [J]. Laboratory Medicine, 2020, 35(1): 6-10.
[7]	SHU Ming, JIN Lu, CHEN Qiuying. Role of serum hepcidin in the diagnosis of myocardial damage among coronary heart disease patients [J]. Laboratory Medicine, 2019, 34(9): 783-786.
[8]	TONG Minghong, DING Hui, JIANG Yinting, SUN Hanxiao, XUAN Binbin, SHENG Huiming. Role of the determination of statin metabolism-related gene in the treatment of cardiovascular and cerebrovascular diseases [J]. Laboratory Medicine, 2019, 34(6): 491-497.
[9]	DING Ning, CHEN Changqiang, FAN Qishi. Correlations of RDW and TB with coronary heart disease and the extent of coronary atherosclerosis [J]. Laboratory Medicine, 2019, 34(10): 889-893.
[10]	YANG Xuesong, SUN Fenyong, LI Zebing, WANG Jian. Roles of nitric oxide,endothelin-1 and homocysteine for the auxiliary diagnosis of coronary heart disease [J]. Laboratory Medicine, 2018, 33(4): 316-320.
[11]	ZHANG Shaohong, SHEN Xuebin. CYP2C19 gene polymorphism in the drug therapy of coronary heart disease [J]. Laboratory Medicine, 2018, 33(11): 979-982.
[12]	YANG Yan, ZHANG Fujun, SHEN Songkun, WANG Houzhao. NT-proBNP,cTnI,Hcy,DD and hs-CRP for the diagnosis of coronary heart disease by ROC curves [J]. Laboratory Medicine, 2018, 33(1): 15-19.
[13]	HUANG Shengxian, ZHENG Liping, YANG Lan, LU Junjia, ZHU Xu. Relationship of cystatin C and single nucleotide polymorphisms with coronary heart disease in Guangxi [J]. Laboratory Medicine, 2017, 32(7): 597-602.
[14]	TONG Minghong, TAO Rongxia, LI Ying, WANG Zi, DING Hui, DENG Chenxia, CAO Yanan, SHENG Huiming. Correlations of apolipoprotein E and lipoprotein（a） with coronary heart disease [J]. Laboratory Medicine, 2017, 32(6): 490-494.
[15]	GU Keping, WANG Yaping, YU Wei, ZHANG Min, GONG Mengjiao, JIANG Yuhai. Receiver operating characteristic curve for free fatty acid determination in patients with coronary heart disease [J]. Laboratory Medicine, 2017, 32(5): 367-369.